| Category | Details |
| Definition | Cachexia and anorexia are conditions characterized by severe loss of appetite and unintentional weight loss, often associated with chronic illnesses such as cancer, HIV/AIDS, and advanced organ failure. |
| Global Epidemiology | – Affects up to 9 million cancer patients worldwide annually, with cachexia present in 50–80% of advanced-stage cases. |
| – Common in chronic conditions such as heart failure (~15% prevalence) and chronic obstructive pulmonary disease (COPD) (~20–40% prevalence). | |
| Prevalence in Key Regions | – United States: ~0.6 million cancer patients with cachexia; high prevalence in advanced HIV/AIDS cases. |
| – European Union: Estimated 3 million cancer cachexia cases annually; high burden in elderly populations. | |
| – India: ~1 million cancer-related cachexia cases annually, with significant unmet needs. | |
| – China: Over 2 million cachexia cases annually, driven by cancer and chronic diseases. | |
| – Caribbean: Estimated ~100,000 cases annually, primarily cancer and HIV-related, with gaps in access to palliative care. | |
| Medicinal Cannabis Approvals | – United States (FDA): Dronabinol (synthetic THC) approved for anorexia associated with weight loss in AIDS patients since 1992. Dronabinol, marketed under the brand name Marinol, was first approved by the U.S. Food and Drug Administration (FDA) in 1985 for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who had failed to respond to conventional antiemetics. It was later indicated for anorexia associated with weight loss in patients with AIDS. |
| – Canada: Nabilone was first approved by Health Canada in 1981 for the treatment of severe nausea and vomiting associated with cancer chemotherapy. ; off-label use for cachexia common. | |
| – European Union (EMA): Limited approvals; dronabinol and nabiximols used off-label for appetite stimulation in cachexia. | |
| – Australia (TGA): Nabiximols (marketed as Sativex) is registered in Australia for the treatment of moderate to severe spasticity due to multiple sclerosis in patients who have not responded adequately to other anti-spasticity medications. It is not specifically approved for the management of anorexia or cachexia. The approval is focused on its efficacy in treating spasticity symptoms rather than appetite stimulation or cachexia management Both dronabinol and nabiximols may be used off-label for conditions such as cachexia and anorexia, but this use is not officially sanctioned by the Therapeutic Goods Administration (TGA). Off-label prescribing is common in clinical practice, particularly for managing symptoms associated with chronic illnesses, including cancer and HIV/AIDS | |
| – Israel: Cannabis-based treatments authorized for cachexia and anorexia management in 2013. | |
| Therapeutic Cannabinoids | – THC (Tetrahydrocannabinol): Stimulates appetite through CB1 receptor activation; primary component in dronabinol. |
| – CBD (Cannabidiol): Modulates inflammatory responses and complements THC for appetite stimulation. | |
| – CBG (Cannabigerol): Emerging evidence suggests a role in appetite regulation and cachexia management. | |
| Mechanism of Action | – THC: Activates CB1 receptors in the hypothalamus, enhancing appetite and reducing nausea. |
| – CBD: Reduces inflammation and oxidative stress, improving overall health in cachexia patients. | |
| – CBG: Modulates endocannabinoid signaling to regulate appetite and energy balance. | |
| Key Clinical Studies | – Strasser et al., 2006: Dronabinol significantly improved appetite in cancer cachexia patients. |
| – Plasse et al., 1991: Early trials demonstrated THC’s efficacy in appetite stimulation among HIV/AIDS patients. | |
| – Borrelli et al., 2020: Cannabinoids showed potential in reducing inflammatory markers and improving appetite in cachexia. | |
| Dosage Guidelines | – Dronabinol (Oral): Initial dose 2.5 mg twice daily before meals; can be titrated to a maximum of 10 mg twice daily based on response. |
| – CBD (Oral): 20–40 mg/day; used adjunctively to THC for anti-inflammatory benefits. | |
| – THC (Inhaled): 2–5 mg per session for immediate appetite stimulation; caution for psychoactive effects. | |
| Administration Methods | – Oral Capsules: Preferred for consistent dosing; slower onset (30–90 minutes). |
| – Sublingual Oils: Provides rapid absorption; useful for acute appetite stimulation. | |
| – Inhalation: Effective for immediate symptom relief but limited by variability in dosing. | |
| Adverse Effects | – THC: Psychoactive effects such as dizziness, anxiety, and cognitive impairment; potential for dependence. |
| – CBD: Mild side effects include fatigue, diarrhea, and appetite changes. | |
| Research Gaps | – Long-term safety and efficacy studies of cannabinoids in cachexia and anorexia management are needed. |
| – Comparative studies with standard appetite stimulants like megestrol acetate are lacking. | |
| Opportunities in the Caribbean | – High Prevalence: Estimated ~100,000 cases annually, with limited access to palliative care and appetite stimulants. |
| – Medical Tourism: Cannabis-based appetite stimulants could attract international patients seeking innovative therapies. | |
| – Research Initiatives: Collaborations could position the Caribbean as a hub for cannabinoid-based cachexia treatments. |
